Santhera's AGAMREE Revenue Surges 98% on Global Expansion
Event summary
- Santhera's total revenue grew 98% to CHF 77.4 million in 2025, driven by AGAMREE adoption in Europe and the U.S.
- AGAMREE product sales increased 72% to CHF 25.8 million, with strong growth in Germany, Austria, and early U.K. sales.
- Santhera received a USD 12.5 million milestone payment from Catalyst after U.S. sales exceeded USD 100 million in 2025.
- Santhera signed a USD 205 million licensing agreement with Nxera Pharma for Japan, South Korea, Australia, and New Zealand.
- The company expects to reach cash breakeven in Q3 2026 without additional funding.
The big picture
Santhera's 98% revenue growth underscores AGAMREE's accelerating adoption as a Duchenne muscular dystrophy treatment, positioning the company as a leader in rare disease therapeutics. The Nxera deal extends its global reach, while long-term data reinforcing AGAMREE's safety and efficacy could further boost sales. The company's strategic partnerships and upcoming launches will be critical in sustaining this momentum.
What we're watching
- Regulatory Timing
- The pace at which Santhera secures reimbursement and launches AGAMREE in Spain, Italy, and Nordic markets will determine 2026 revenue growth.
- Commercial Execution
- Whether Santhera can sustain AGAMREE's strong adoption in Europe and the U.S. while expanding into new territories like Japan and China.
- Cash Flow Management
- How Santhera's path to cash breakeven in Q3 2026 will be impacted by inventory requirements and global rollout costs.
Related topics